Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where soggetti phrase all words 'CYP2C SUBFAMILY' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 48 riferimenti
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Gervasini, G; Martinez, C; Agundez, JAG; Garcia-Gamito, FJ; Benitez, J
      Inhibition of cytochrome P4502C9 activity in vitro by 5-hydroxytryptamine and adrenaline

      PHARMACOGENETICS
    2. Niwa, T; Fujimoto, M; Kishimoto, K; Yabusaki, Y; Ishibashi, F; Katagiri, M
      Metabolism and interaction of bisphenol A in human hepatic cytochrome p450and steroidogenic CYP17

      BIOLOGICAL & PHARMACEUTICAL BULLETIN
    3. Ensom, MHH; Chang, TKH; Patel, P
      Pharmacogenetics - The therapeutic drug monitoring of the future?

      CLINICAL PHARMACOKINETICS
    4. Mamiya, K; Kojima, K; Yukawa, E; Higuchi, S; Ieiri, I; Ninomiya, H; Tashiro, N
      Phenytoin intoxication induced by fluvoxamine

      THERAPEUTIC DRUG MONITORING
    5. Spear, BB
      Pharmacogenetics and antiepileptic drugs

      EPILEPSIA
    6. Brandolese, R; Scordo, MG; Spina, E; Gusella, M; Padrini, R
      Severe phenytoin intoxication in a subject homozygous for CYP2C9*3

      CLINICAL PHARMACOLOGY & THERAPEUTICS
    7. Ninomiya, H; Mamiya, K; Matsuo, S; Ieiri, I; Higuchi, S; Tashiro, N
      Genetic polymorphism of the CYP2C subfamily and excessive serum phenytoin concentration with central nervous system intoxication

      THERAPEUTIC DRUG MONITORING
    8. Komatsu, K; Ito, K; Nakajima, Y; Kanamitsu, S; Imaoka, S; Funae, Y; Green, CE; Tyson, CA; Shimada, N; Sugiyama, Y
      Prediction of in vivo drug-drug interactions between tolbutamide and various sulfonamides in humans based on in vitro experiments

      DRUG METABOLISM AND DISPOSITION
    9. Tuvesson, H; Wienkers, LC; Gunnarsson, PO; Seidegard, J; Persson, R
      Identification of cytochrome P4503A as the major subfamily responsible forthe metabolism of roquinimex in man

      XENOBIOTICA
    10. Abernethy, DR; Flockhart, DA
      Molecular basis of cardiovascular drug metabolism - Implications for predicting clinically important drug interactions

      CIRCULATION
    11. Bachmann, KA; Belloto, RJ
      Differential kinetics of phenytoin in elderly patients

      DRUGS & AGING
    12. Kidd, RS; Straughn, AB; Meyer, MC; Blaisdell, J; Goldstein, JA; Dalton, JT
      Pharmacokinetics of chlorpheniramine, phenytoin, glipizide and nifedipine in an individual homozygous for the CYP2C9*3 allele

      PHARMACOGENETICS
    13. Aynacioglu, AS; Brockmoller, J; Bauer, S; Sachse, C; Guzelbey, P; Ongen, Z; Nacak, M; Roots, I
      Frequency of cytochrome P450CYP2C9 variants in a Turkish population and functional relevance for phenytoin

      BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
    14. Baldwin, SJ; Clarke, SE; Chenery, RJ
      Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of rosiglitazone

      BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
    15. Taguchi, K; Konishi, T; Nishikawa, H; Kitamura, S
      Identification of human cytochrome P450 isoforms involved in the metabolism of S-2-[4-(3-methyl-2-thienyl)phenyl]propionic acid

      XENOBIOTICA
    16. McCrea, JB; Cribb, A; Rushmore, T; Osborne, B; Gillen, L; Lo, MW; Waldman, S; Bjornsson, T; Spielberg, S; Goldberg, MR
      Phenotypic and genotypic investigations of a healthy volunteer deficient in the conversion of losartan to its active metabolite E-3174

      CLINICAL PHARMACOLOGY & THERAPEUTICS
    17. MINERS JO; BIRKETT DJ
      CYTOCHROME P4502C9 - AN ENZYME OF MAJOR IMPORTANCE IN HUMAN DRUG-METABOLISM

      British journal of clinical pharmacology
    18. EAGLING VA; TJIA JF; BACK DJ
      DIFFERENTIAL SELECTIVITY OF CYTOCHROME-P450 INHIBITORS AGAINST PROBE SUBSTRATES IN HUMAN AND RAT-LIVER MICROSOMES

      British journal of clinical pharmacology
    19. ZWEERSZEILMAKER WM; HORBACH GJ; WITKAMP RF
      EFFECTS OF NON STEROIDAL ANTIINFLAMMATORY DRUGS AND SULFONAMIDES ON HEPATIC CYTOCHROME P4502C ACTIVITY IN-VITRO IN GOATS AND CATTLE

      Journal of veterinary pharmacology and therapeutics
    20. HICKMAN D; WANG JP; WANG Y; UNADKAT JD
      EVALUATION OF THE SELECTIVITY OF IN-VITRO PROBES AND SUITABILITY OF ORGANIC-SOLVENTS FOR THE MEASUREMENT OF HUMAN CYTOCHROME-P450 MONOOXYGENASE ACTIVITIES

      Drug metabolism and disposition
    21. NAKAJIMA M; INOUE T; SHIMADA N; TOKUDOME S; YAMAMOTO T; KUROIWA Y
      CYTOCHROME-P450 2C9 CATALYZES INDOMETHACIN O-DEMETHYLATION IN HUMAN LIVER-MICROSOMES

      Drug metabolism and disposition
    22. YAMAZAKI H; INOUE K; SHIMADA T
      ROLES OF 2 ALLELIC VARIANTS (ARG144CYS AND ILE359LEU) OF CYTOCHROME P4502C9 IN THE OXIDATION OF TOLBUTAMIDE AND WARFARIN BY HUMAN LIVER-MICROSOMES

      Xenobiotica
    23. ONG CE; MINERS JO; BIRKETT DJ; BHASKER CR
      BACULOVIRUS-MEDIATED EXPRESSION OF CYTOCHROME P4502C8 AND HUMAN NADPH-CYTOCHROME P450 REDUCTASE - OPTIMIZATION OF PROTEIN EXPRESSION

      Xenobiotica
    24. ANDERSSON T; BREDBERG E; LAGERSTROM PO; NAESDAL J; WILSON I
      LACK OF DRUG-DRUG INTERACTION BETWEEN 3 DIFFERENT NONSTEROIDAL ANTIINFLAMMATORY DRUGS AND OMEPRAZOLE

      European Journal of Clinical Pharmacology
    25. EDWARDS RJ; ADAMS DA; WATTS PS; DAVIES DS; BOOBIS AR
      DEVELOPMENT OF A COMPREHENSIVE PANEL OF ANTIBODIES AGAINST THE MAJOR XENOBIOTIC-METABOLIZING FORMS OF CYTOCHROME-P450 IN HUMANS

      Biochemical pharmacology
    26. YAMAZAKI H; INOUE K; CHIBA K; OZAWA N; KAWAI T; SUZUKI Y; GOLDSTEIN JA; GUENGERICH FP; SHIMADA T
      COMPARATIVE-STUDIES ON THE CATALYTIC ROLES OF CYTOCHROME-P450-2C9 ANDITS CYS-VARIANTS AND LEU-VARIANTS IN THE OXIDATION OF WARFARIN, FLURBIPROFEN, AND DICLOFENAC BY HUMAN LIVER-MICROSOMES

      Biochemical pharmacology
    27. HORSMANS Y; VANDENBERGE V; BOUCKAERT A; DESAGER JP
      PHENYTOIN HYDROXYLATION IN A HEALTHY CAUCASIAN POPULATION - BIMODAL DISTRIBUTION OF HYDROXYPHENYTOIN URINARY-EXCRETION

      Pharmacology & toxicology
    28. IEIRI I; MAMIYA K; URAE A; WADA Y; KIMURA M; IRIE S; AMAMOTO T; KUBOTA T; YOSHIOKA S; NAKAMURA K; NAKANO S; TASHIRO N; HIGUCHI S
      STEREOSELECTIVE 4'-HYDROXYLATION OF PHENYTOIN - RELATIONSHIP TO (S)-MEPHENYTOIN POLYMORPHISM IN JAPANESE

      British journal of clinical pharmacology
    29. SHIMIZU Y; KUSUNOSE E; KIKUTA Y; ARAKAWA T; ICHIHARA K; KUSUNOSE M
      PURIFICATION AND CHARACTERIZATION OF 2 NEW CYTOCHROME-P-450 RELATED TO CYP2C SUBFAMILY FROM RABBIT SMALL-INTESTINE MICROSOMES

      Biochimica et biophysica acta. Protein structure and molecular enzymology
    30. ZHANG ZY; KERR J; WEXLER RS; LI HY; ROBINSON AJ; HARLOW PP; KAMINSKY LS
      WARFARIN ANALOG INHIBITION OF HUMAN CYP2C9-CATALYZED S-WARFARIN 7-HYDROXYLATION

      Thrombosis research
    31. HAMMAN MA; THOMPSON GA; HALL SD
      REGIOSELECTIVE AND STEREOSELECTIVE METABOLISM OF IBUPROFEN BY HUMAN CYTOCHROME-P450 2C

      Biochemical pharmacology
    32. SULLIVANKLOSE TH; GHANAYEM BI; BELL DA; ZHANG ZY; KAMINSKY LS; SHENFIELD GM; MINERS JO; BIRKETT DJ; GOLDSTEIN JA
      THE ROLE OF THE CYP2C9-LEU(359) ALLELIC VARIANT IN THE TOLBUTAMIDE POLYMORPHISM

      Pharmacogenetics
    33. BORT R; PONSODA X; CARRASCO E; GOMEZLECHON MJ; CASTELL JV
      METABOLISM OF ACECLOFENAC IN HUMANS

      Drug metabolism and disposition
    34. BAJPAI M; ROSKOS LK; SHEN DD; LEVY RH
      ROLES OF CYTOCHROME P4502C9 AND CYTOCHROME P4502C19 IN THE STEREOSELECTIVE METABOLISM OF PHENYTOIN TO ITS MAJOR METABOLITE

      Drug metabolism and disposition
    35. JEAN P; LOPEZGARCIA P; DANSETTE P; MANSUY D; GOLDSTEIN JL
      OXIDATION OF TIENILIC ACID BY HUMAN YEAST-EXPRESSED CYTOCHROMES P-4502C8, 2C9, 2C18 AND 2C19 - EVIDENCE THAT THIS DRUG IS A MECHANISM-BASED INHIBITOR SPECIFIC FOR CYTOCHROME-P-450 2C9

      European journal of biochemistry
    36. TRACY TS; MARRA C; WRIGHTON SA; GONZALEZ FJ; KORZEKWA KR
      STUDIES OF FLURBIPROFEN 4'-HYDROXYLATION - ADDITIONAL EVIDENCE SUGGESTING THE SOLE INVOLVEMENT OF CYTOCHROME-P450 2C9

      Biochemical pharmacology
    37. HAINING RL; HUNTER AP; VERONESE ME; TRAGER WF; RETTIE AE
      ALLELIC VARIANTS OF HUMAN CYTOCHROME-P450 2C9 - BACULOVIRUS-MEDIATED EXPRESSION, PURIFICATION, STRUCTURAL CHARACTERIZATION, SUBSTRATE STEREOSELECTIVITY, AND PROCHIRAL SELECTIVITY OF THE WILD-TYPE AND I359L MUTANT FORMS

      Archives of biochemistry and biophysics
    38. ONO S; TSUTSUI M; GONZALEZ FJ; SATOH T; MASUBUCHI Y; HORIE T; SUZUKI T; NARIMATSU S
      OXIDATIVE-METABOLISM OF BUNITROLOL BY COMPLEMENTARY DNA-EXPRESSED HUMAN CYTOCHROME-P450 ISOZYMES IN A HUMAN HEPATOMA-CELL LINE (HEP G2) USING RECOMBINANT VACCINIA VIRUS

      Pharmacogenetics
    39. CRIBB AE; SPIELBERG SP; GRIFFIN GP
      N-4-HYDROXYLATION OF SULFAMETHOXAZOLE BY CYTOCHROME-P450 OF THE CYTOCHROME P4502C SUBFAMILY AND REDUCTION OF SULFAMETHOXAZOLE HYDROXYLAMINEIN HUMAN AND RAT HEPATIC MICROSOMES

      Drug metabolism and disposition
    40. BALDWIN SJ; BLOOMER JC; SMITH GJ; AYRTON AD; CLARKE SE; CHENERY RJ
      KETOCONAZOLE AND SULFAPHENAZOLE AS THE RESPECTIVE SELECTIVE INHIBITORS OF P4503A AND 2C9

      Xenobiotica
    41. BUSSE D; COSME J; BEAUNE P; KROEMER HK; EICHELBAUM M
      CYTOCHROMES OF THE P450 2C SUBFAMILY ARE THE MAJOR ENZYMES INVOLVED IN THE O-DEMETHYLATION OF VERAPAMIL IN HUMANS

      Naunyn-Schmiedeberg's archives of pharmacology
    42. SONNICHSEN DS; LIU Q; SCHUETZ EG; SCHUETZ JD; PAPPO A; RELLING MV
      VARIABILITY IN HUMAN CYTOCHROME-P450 PACLITAXEL METABOLISM

      The Journal of pharmacology and experimental therapeutics
    43. MANCY A; BROTO P; DIJOLS S; DANSETTE PM; MANSUY D
      THE SUBSTRATE-BINDING SITE OF HUMAN LIVER CYTOCHROME-P450 2C9 - AN APPROACH USING DESIGNED TIENILIC ACID-DERIVATIVES AND MOLECULAR MODELING

      Biochemistry
    44. INOUE K; INAZAWA J; SUZUKI Y; SHIMADA T; YAMAZAKI H; GUENGERICH FP; ABE T
      FLUORESCENCE IN-SITU HYBRIDIZATION ANALYSIS OF CHROMOSOMAL LOCALIZATION OF 3 HUMAN CYTOCHROME-P450-2C GENES (CYP2C8, 2C9, AND 2C10) AT 10Q24.1

      Japanese journal of human genetics
    45. CHIBA K; SAITOH A; KOYAMA E; TANI M; HAYASHI M; ISHIZAKI T
      THE ROLE OF S-MEPHENYTOIN 4'-HYDROXYLASE IN IMIPRAMINE METABOLISM BY HUMAN LIVER-MICROSOMES - A 2-ENZYME KINETIC-ANALYSIS OF N-DEMETHYLATION AND 2-HYDROXYLATION

      British journal of clinical pharmacology
    46. HALL SD; HAMMAN MA; RETTIE AE; WIENKERS LC; TRAGER WF; VANDENBRANDEN M; WRIGHTON SA
      RELATIONSHIPS BETWEEN THE LEVELS OF CYTOCHROME P4502C9 AND ITS PROTOTYPIC CATALYTIC ACTIVITIES IN HUMAN LIVER-MICROSOMES

      Drug metabolism and disposition
    47. RAHMAN A; KORZEKWA KR; GROGAN J; GONZALEZ FJ; HARRIS JW
      SELECTIVE BIOTRANSFORMATION OF TAXOL TO 6-ALPHA-HYDROXYTAXOL BY HUMANCYTOCHROME-P450 2C8

      Cancer research
    48. RAHMAN A; KORZEKWA KR; GROGAN J; GONZALEZ FJ; HARRIS JW
      SELECTIVE BIOTRANSFORMATION OF TAXOL TO 6-ALPHA-HYDROXYTAXOL BY HUMANCYTOCHROME-P450 2C8

      Cancer research


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 26/05/20 alle ore 20:02:58